Routine immunization profile **Monaco**



Progress towards achieving European Vaccine Action Plan goals, 2017

Goal	Indicator	Status	Goal	Indicator	Status
1	Sustain polio-free status ^a (Current risk)	Yes (Intermediate)	4	Meets vaccination coverage targets DTP3 national immunization coverage ≥95% ^d ≥90% DTP3 coverage achieved in ≥90% of districts* ^e	Yes Yes ND
2	Measles elimination status ^b	Eliminated	_	Make evidence-based decisions about introduction of new vaccines**e	Yes
2	Rubella elimination status ^b	Eliminated	5	NITAG made a recommendation about PCV NITAG made a recommendation about RV NITAG made a recommendation about HPV	Yes Yes Yes
3	Control hepatitis B infection ^c	Validation pending	6	Achieve financial sustainability of the national immunization programme***	Yes

^{*}Only one administrative level in the country

Demographic, income and health expenditure summary, 2017

Total Population ^f	38 695
Live births	453
Surviving infants	449
<5 years	2277
<15 years	6997
Neonatal mortality rate (per 1000 live births) ^f	1.7
Infant mortality rate (per 1000 live births) ^f	2.7
Number of districts ^e	1
GNI (per capita, in USD) ^g	ND
Health spending as % of total government expenditure ^g	8



Immunization schedule, 2017e

2M	DTaPHib, DTIPV, HepB_Pediatric, HIB, PCV				
3M	DTaPHibIPV				
4M	DTaPHibHepBIPV, DTIPV, HepB_ Pediatric, HIB, PCV				
5M	MenC_conj				
11M	DTIPV, HepB_Pediatric, HIB				
12M	MenC_conj, MMR, PCV				
16M	MMR				
16-18M	DTaPHibHepBIPV				
6Y	DTIPV				
11Y	HPV*				
11-13Y	DTaPIPV				
26-28Y	DTaPIPV, IPV, TdaPIPV				
*Second dose ±6M					

Second dose +6M

Note: Diphtheria, tetanus, and poliovirus vaccines are mandatory; other vaccines in the immunization schedule are recommended^L

^{**}New vaccines introduced or not introduced based on NITAG evidence-based recommendations

^{***}Country self-sufficient for procuring routine vaccines



Vaccine coverage estimates, 2013-2017^d


	2013	2014	2015	2016	2017
BCG	89	89	89	89	89
HepB-BD	NR	NR	NR	NR	NR
DTP1	99	99	99	99	99
DTP3	99	99	99	99	99
HepB3	99	99	99	99	99
Hib3	99	99	99	99	99
Pol3	99	99	99	99	99
PCV3	ND	ND	ND	ND	ND
Rotac	NR	NR	NR	NR	NR
RCV1	90	89	88	88	87
MCV1	90	89	88	88	87
MCV2	ND	79	79	79	79
	100		50		0 ND NR

Number of reported cases of vaccine-preventable diseases, 2013-2017^{e,i}


	2013*	2014*	2015*	2016*	2017
Measles					1
Mumps					ND
Rubella					ND
Congenital rubella syndrome					0
Diphtheria					0
Tetanus					0
Pertussis					0
Hepatitis A					ND
Varicella					ND

^{*}No JRF submitted

Number of reported measles, mumps and rubella cases^e and MCV coverage estimates^d, 2013-2017



Number of reported diphtheria, tetanus and pertussis cases^e and DTP3 coverage estimates^d, 2013-2017




Surveillance with laboratory confirmation of cases, 2017^e

Measles	Yes
Rubella	No
Congenital rubella syndrome	No
Rotavirus	No
Invasive meningococcal disease	No
Invasive pneumococcal disease	No
Invasive <i>Haemophilus influenzae</i> disease	No

Note: Case-based surveillance (with laboratory confirmation of cases) assessed for measles, rubella, and congenital rubella syndrome. Hospital-based sentinel surveillance and/or population-based surveillance (both with laboratory confirmation of cases) assessed for rotavirus, invasive meningococcal disease, invasive pneumococcal disease, and invasive Haemophilus influenzae disease.

DTP1-DTP3 dropout rate, 2013-2017^d



Note: propout rate is calculated using WUENIC





Immunization system characteristics, 2017

Sustained access to WHO accredited polio, measles, and rubella laboratories ^h	Yes	
NITAG in place that meets six WHO criteria ^e	No	
National system in place to monitor AEFIs ^e	No	
Communication plan in place to respond to vaccine safety-related events ^e		
Vaccine hesitancy assessment performed within last 5 years ^e		
Mandatory proof of immunization at school entry ^e		

Note: The six WHO NITAG criteria are 1. legislative or administrative basis for the advisory group; 2. formal written terms of reference; 3. at least five different areas of expertise represented among core members; 4. at least one meeting per year; 5. circulation of the agenda and background documents at least one week prior to meetings; 6. mandatory disclosure of any conflict of interest

Vaccine stockouts by administrative levele,i, 2013-2017





Abbreviations

AEFI	Adverse event following immunization	MCV1	measles-mumps-rubella vaccine, first dose
BCG	Bacille Calmette-Guerin vaccine for tuberculosis	MCV2	measles-mumps-rubella vaccine, second dose
CRS	congenital Rubella Syndrome	MMR	measles-mumps-rubella vaccine
DT	diptheria-tetanus-containing vaccine	ND	Data not available
DTP	diptheria-tetanus-pertussis-containing vaccine	NITAG	National Immunization Technical Advisory Group
DTP1	diphtheria-tetanus-pertussis-containing vaccine, first dose	NR	Not relevant as vaccine not included in immunization schedule
DTP3	diphtheria-tetanus-pertussis-containing vaccine, third dose	OPV	oral polio vaccine
GNI	Gross national income	PCV	pneumococcal conjugate vaccine
НерВ	hepatitis B	PCV3	pneumococcal conjugate vaccine , third dose
HepB3	hepatitis B vaccine, third dose	Pol3	polio-containing vaccine, third dose
HepB-BD	hepatitis B vaccine, birth dose	RCV1	rubella-containing vaccine, first dose
Hib	Haemophilus influenzae type b	Rotac	rotavirus vaccine-complete series
Hib3	Haemophilus influenzae type b vaccine, third dose	Td	tetanus-diphtheria-containing vaccine
HPV	human papillomavirus	TT	tetanus toxoid vaccine
IPV	inactivated polio vaccine	W,M,Y	Weeks, Months, Years
MCV	measles-containing vaccine		

^{*}Data on HPV stockouts have only been collected in JRF since 2016

^{**} No JRF Submitted

Routine immunization profile **Monaco**



Data sources

- a European Regional Commission for Certification of Poliomyelitis eradication (RCC) meeting report: www.euro.who.int/32ndRCC
- b European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/7thRVC
- c European Vaccine Action Plan 2015-2020 Midterm report
- d WHO/UNICEF Estimates of National Immunization Coverage (WUENIC): (http://www.who.int/immunization/monitoring_surveillance/data/en/)
- e WHO/UNICEF Joint Reporting Form on immunization (JRF)
- f World Population Prospects: The 2017 Revision, New York, United Nations
- g World Bank, World Development Indicators
- h Polio Laboratory Network: www.euro.who.int/poliolabnetwork & Personal communication based on annual accreditation process of the European Measles and Rubella Laboratory Network
- i Communication with the country